Coagulation factor IX-dependent intrinsic tenase complex (Intrinsic tenase)

The coagulation factor IX-dependent intrinsic tenase complex is a multi-component enzyme assembly essential for the amplification phase of the blood coagulation cascade. It consists of the serine protease activated factor IX (FIXa), the non-enzymatic cofactor activated factor VIII (FVIIIa), calcium ions, and a procoagulant phospholipid surface, typically provided by activated platelets (Source: UniProt, P00740; Source: UniProt, P00451). The primary biological role of this complex is to catalyze the proteolytic activation of factor X into factor Xa, which is a critical step preceding the prothrombinase complex formation and subsequent thrombin burst (Source: StatPearls, Physiology, Coagulation Cascade, 2023). This assembly increases the catalytic efficiency of factor X activation by approximately 100,000-fold compared to factor IXa alone (Source: Journal of Thrombosis and Haemostasis, 2009). Deficiencies in the components of this complex lead to severe bleeding disorders, most notably Hemophilia A (FVIII deficiency) and Hemophilia B (FIX deficiency). Modern therapeutic strategies, such as the bispecific antibody emicizumab, target this complex by mimicking the function of FVIIIa to bridge FIXa and FX, thereby restoring hemostatic function in patients with inhibitors (Source: FDA, Hemlibra Prescribing Information). Monitoring the activity of this complex through assays like aPTT or thrombin generation is vital for managing bleeding risks and ensuring the efficacy of replacement or bypass therapies.

Other names

Intrinsic tenase complexFIXa-FVIIIa complexFactor IXa-Factor VIIIa complexTenase complex

Drugs targeting the intrinsic tenase complex primarily act through factor replacement (restoring FIX or FVIII levels) or by mimicking the cofactor function of FVIIIa to bridge FIXa and FX (e.g., bispecific antibodies), thereby facilitating the proteolytic activation of Factor X to Factor Xa (Source: FDA, Hemlibra Prescribing Information; Source: StatPearls, 2023).